Abstracts tagged "psoriatic arthritis and tobacco use"

Abstract Number: 2762 • 2016 ACR/ARHP Annual Meeting
Smoking and Severity of Psoriatic Arthritis
Sahithi Jarugula¹, Bonita Libman², Amanda Kennedy³ and Diantha Howard⁴, ¹Internal Medicine, Sahithi Jarugula, S.Burlington, VT, ²Internal Medicine, University of Vermont Medical Center, Burlington, VT, ³Internal Medicine, University of Vermont Medical center, Burlington, VT, ⁴Statistics, University of Vermont, Burlington, VT
Background/Purpose: Smoking is a major modifiable risk factor for various inflammatory diseases including rheumatoid arthritis 1, 2 and psoriasis 3,4,5. The presence of cyclic citrullinated…
Abstract Number: 3096 • 2016 ACR/ARHP Annual Meeting
Association Between Smoking and Psoriatic Arthritis Among Psoriasis Patients and the General Population: Data from National Inpatient Sample
Paras Karmacharya¹, Dilli Poudel¹, Rashmi Dhital² and Pragya Shrestha³, ¹Internal Medicine, Reading Health System, WEST READING, PA, ²Universal College of Medical Sciences, MBBS, Kathmandu, Nepal, ³Internal medicine, Reading Health System, West Reading, PA
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory arthritis affecting approximately 520,000 patients in the US and up to one third of patients with psoriasis. Studies…
Abstract Number: 1568 • 2014 ACR/ARHP Annual Meeting
Joint Damage Is Not Associated with Smoking Status in Patients with Psoriatic Arthritis
Hernán Maldonado-Ficco¹, Arane Thavaneswaran², Vinod Chandran² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: The association between smoking and radiographic progression has been established in axial spondyloarthritides and rheumatoid arthritis (RA) but this association has not been established…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].